Compass Therapeutics Inc.
NASDAQ:CMPX
Intrinsic Value
The intrinsic value of one CMPX stock under the Base Case scenario is 5.43 USD. Compared to the current market price of 3.33 USD, Compass Therapeutics Inc. is Undervalued by 39%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Compass Therapeutics Inc.
Loading...
Fundamental Analysis

Revenue & Expenses Breakdown
Compass Therapeutics Inc.
Balance Sheet Decomposition
Compass Therapeutics Inc.
Current Assets | 132.8m |
Cash & Short-Term Investments | 126.7m |
Other Current Assets | 6m |
Non-Current Assets | 7.7m |
PP&E | 7.1m |
Other Non-Current Assets | 568k |
Free Cash Flow Analysis
Compass Therapeutics Inc.
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Compass Therapeutics Inc.
Revenue
|
850k
USD
|
Operating Expenses
|
-57.5m
USD
|
Operating Income
|
-56.6m
USD
|
Other Expenses
|
7.3m
USD
|
Net Income
|
-49.4m
USD
|
CMPX Profitability Score
Profitability Due Diligence
Compass Therapeutics Inc.'s profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Compass Therapeutics Inc.'s profitability score is 16/100. The higher the profitability score, the more profitable the company is.
CMPX Solvency Score
Solvency Due Diligence
Compass Therapeutics Inc.'s solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Compass Therapeutics Inc.'s solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CMPX Price Targets Summary
Compass Therapeutics Inc.
According to Wall Street analysts, the average 1-year price target for CMPX is 13.06 USD with a low forecast of 6.06 USD and a high forecast of 33.6 USD.
Dividends
Current shareholder yield for CMPX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one CMPX stock under the Base Case scenario is 5.43 USD.
Compared to the current market price of 3.33 USD, Compass Therapeutics Inc. is Undervalued by 39%.